http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Campone, Mario (검색결과 5 건)
- 무료
- 기관 내 무료
- 유료
-
-
Rugo, Hope S.,Tré,dan, Olivier,Ro, Jungsil,Morales, Serafin M.,Campone, Mario,Musolino, Antonino,Afonso, Noé,mia,Ferreira, Marta,Park, Kyong Hwa,Cortes, Javier,Tan, Antoinette R.,Blum, Joa Springer-Verlag 2017 Breast cancer research and treatment Vol.165 No.3
<P>R/D/E did not improve PFS compared with R/E. Because the PFS reported for R/E was similar to that reported for everolimus plus exemestane in patients with advanced breast cancer, it is possible that lower-dose ridaforolimus in the R/D/E arm (from overlapping toxicities with IGF1R inhibitor) contributed to lack of improved PFS.</P>
-
Denis Dupoiron,Lila Autier,Nathalie Lebrec,Valérie Seegers,Caroline Folliard,Anne Patsouris,Mario Campone,Paule Augereau 한국유방암학회 2023 Journal of breast cancer Vol.26 No.6
Purpose: Most oncological treatments for leptomeningeal metastasis (LM) do not cross the blood-brain barrier (BBB). One therapeutic option is intrathecal (IT) chemotherapy. Both the brain-implanted Omaya reservoir and lumbar puncture (LP) are classic routes for IT chemotherapy delivery. An intrathecal catheter (IC) connected to a subcutaneous port is a recently developed option for the management of chemotherapy infusions. It is essential to evaluate the efficacy and safety of chemotherapy infusion using such device. Methods: We conducted a retrospective monocentric study within Institut de cancerologie de l’Ouest at Angers, including all patients with advanced breast cancer (aBC) with LM implanted with an IT device for IT chemotherapy between January 2013 and May 2020. The primary endpoint was overall survival (OS) and secondary endpoints included surgical feasibility, patient safety, and progression-free survival (PFS). The catheter was inserted through an LP, the tip was positioned at the right level and connected to a subcutaneous port implanted under the skin of the anterior thoracic wall. IT chemotherapy is painless and easy for qualified nurses to administer on an outpatient basis. Results: Thirty women underwent the implantation. No failures occurred during the procedure. A total of 77% of patients reported no complications after implantation. Only three complications required surgical treatment. The median number of IT chemotherapy courses per patient was 8 (range, 2–27). The tolerance profile for iterative IT chemotherapy was manageable in ambulatory care. With a median follow-up of 76.5 months (95% confidence interval [CI], 11.6–not available), the median OS was 158 days (95% CI, 87–235), and the median PFS was 116 days (95% CI, 58–174). Conclusion: Infusing chemotherapy using an implanted catheter is an efficient option for managing IT chemotherapy with a good tolerance profile. Patient-reported outcomes for the evaluation of IT chemotherapy toxicity are currently being developed.
-
Thomas, Eva S.,Gomez, Henry L.,Li, Rubi K.,Chung, Hyun-Cheol,Fein, Luis E.,Chan, Valorie F.,Jassem, Jacek,Pivot, Xavier B.,Klimovsky, Judith V.,de Mendoza, Fernando Hurtado,Xu, Binghe,Campone, Mario,L Grune & Stratton 2007 Journal of clinical oncology Vol.25 No.33
<B>Purpose</B><P>Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Ixabepilone has single-agent activity in these patients and has demonstrated synergy with capecitabine in this setting. This study was designed to compare ixabepilone plus capecitabine versus capecitabine alone in anthracycline-pretreated or -resistant and taxane-resistant locally advanced or metastatic breast cancer.</P><B>Patients and Methods</B><P>Seven hundred fifty-two patients were randomly assigned to ixabepilone 40 mg/m<SUP>2</SUP>intravenously on day 1 of a 21-day cycle plus capecitabine 2,000 mg/m<SUP>2</SUP>orally on days 1 through 14 of a 21-day cycle, or capecitabine alone 2,500 mg/m<SUP>2</SUP>on the same schedule, in this international phase III study. The primary end point was progression-free survival evaluated by blinded independent review.</P><B>Results</B><P>Ixabepilone plus capecitabine prolonged progression-free survival relative to capecitabine (median, 5.8 v 4.2 months), with a 25% reduction in the estimated risk of disease progression (hazard ratio, 0.75; 95% CI, 0.64 to 0.88; P = .0003). Objective response rate was also increased (35% v 14%; P < .0001). Grade 3/4 treatment-related sensory neuropathy (21% v 0%), fatigue (9% v 3%), and neutropenia (68% v 11%) were more frequent with combination therapy, as was the rate of death as a result of toxicity (3% v 1%, with patients with liver dysfunction [≥ grade 2 liver function tests] at greater risk). Capecitabine-related toxicities were similar for both treatment groups.</P><B>Conclusion</B><P>Ixabepilone plus capecitabine demonstrates superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated or resistant to anthracyclines and resistant to taxanes.</P>
-
Miguel Angel Arrabal-Polo,Francisco Palao-Yago,Iluminada Campon-Pacheco,Maribel Martinez-Sanchez,Armando Zuluaga-Gomez,Miguel Arrabal-Martin 대한비뇨의학회 2012 Investigative and Clinical Urology Vol.53 No.7
Purpose: Overactive bladder (OAB) is a clinical syndrome that is currently treated initially with anticholinergics, although some other therapeutic alternatives exist, such as neuromodulation, botulinum toxin, and posterior tibial nerve stimulation (PTNS). The purpose of this study was to assess the efficacy of PTNS in patients with OAB refractory to anticholinergics. Materials and Methods: We present a cohort study of 14 women with OAB to whom we applied PTNS. We assessed (before and after the treatment) the diurnal micturitional frequency, the nocturnal micturitional frequency, urgency episodes, and urge incontinence episodes. Results were analyzed by using the Wilcoxon test for nonparametric samples. Results: We observed statistically significant improvement in the diurnal micturitional frequency (p=0.05), in episodes of micturitional urgency (p=0.03), and in episodes of urge incontinence (p=0.004). A total of 50% of the patients felt subjective improvement from their pathology. Conclusions: PTNS is a valid, minimally invasive treatment option with minimum morbidity for patients with OAB refractory to treatment with anticholinergics. Purpose: Overactive bladder (OAB) is a clinical syndrome that is currently treated initially with anticholinergics, although some other therapeutic alternatives exist, such as neuromodulation, botulinum toxin, and posterior tibial nerve stimulation (PTNS). The purpose of this study was to assess the efficacy of PTNS in patients with OAB refractory to anticholinergics. Materials and Methods: We present a cohort study of 14 women with OAB to whom we applied PTNS. We assessed (before and after the treatment) the diurnal micturitional frequency, the nocturnal micturitional frequency, urgency episodes, and urge incontinence episodes. Results were analyzed by using the Wilcoxon test for nonparametric samples. Results: We observed statistically significant improvement in the diurnal micturitional frequency (p=0.05), in episodes of micturitional urgency (p=0.03), and in episodes of urge incontinence (p=0.004). A total of 50% of the patients felt subjective improvement from their pathology. Conclusions: PTNS is a valid, minimally invasive treatment option with minimum morbidity for patients with OAB refractory to treatment with anticholinergics.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
